Abemaciclib

阿贝西利

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NameAbemaciclib
Drug Alias Name玻玛西林abemaciclibabemaciclibumBemaciclibVerzenio +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4
Therapy Area/IndicationsBrain metastasesEsophageal adenocarcinomaMetastatic breast cancer +[45] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2017/09/28
Country/TerritoryCzechiaBelgiumCanada +[41] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteWeill Medical College of Cornell UniversityJules Bordet Institute +[15] 
Inactive CompaniesLilly Del Caribe IncUniversity Of Milano BicoccaThe University Of Arizona +[6] 
Active IndicationsBrain metastasesEsophageal adenocarcinomaMetastatic breast cancer +[36] 
Inactive IndicationsHepatic InsufficiencyProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[9] 

Other Information

ATC CodeL01EF03
Related LinksWikipediaDrugBankKEGG